The mission of Case Comprehensive Cancer Center (Case CCC), now in its 27th grant year, is to promote a coordinated, translational research-oriented culture of scientific discovery applied to human cancers, that improves cancer detection, prevention, treatment, cure, and survivorship in Cleveland, Northeast Ohio and around the world, and to disseminate its advances to patients and populations. The Center provides leadership and oversight of collaboration for basic cancer research oriented toward identification of novel therapeutic targets; prevention, control and population research; therapeutic and non-therapeutic clinical research across the disease spectrum; and community outreach. These accomplishments include examples of practice changing impact within the catchment area and nationally. The Center coordinates all aspects of cancer research in Cleveland and Northern Ohio, including activities of the affiliate institutions of Case Western Reserve University, Cleveland Clinic, and University Hospitals. The Center provides opportunities to participate in clinical trials to almost 16,000 cancer patients (over 62% of cancer cases in the catchment area) who are newly diagnosed annually in the region. The Case CCC is organized around 7 Research Programs, 13 Shared Resources, and a clinical and behavioral cancer research infrastructure that prioritizes innovative translational research and investigator-initiated clinical trials that cut across the Research Programs. The Case CCC includes 279 members (172 Full, 32 Associate, and 75 Clinical) from 7 schools and 68 academic departments who actively participate in Center activities including Program and Shared Resource meetings and retreats, and leadership committees, each promoting a transdisciplinary approach that facilitates discovery and clinical application. The cancer focus of the Center is exceptional, with over $77M in direct funding and over $26M in direct NCI funding. Institutional commitment is also exceptional, codified through an updated Memorandum of Understanding. The consortium members will provide over $128M of internal funds for cancer research in the next grant cycle. The Case CCC and its affiliate institutions have established an outstanding infrastructure that enables its members to improve the prevention, diagnosis, and treatment of cancer through discovery, implementation and dissemination, and collaborative transdisciplinary research while providing state-of-the-art care and treatment to cancer patients and their families. The Case CCC yields tangible benefits as an active partner with the NCI by supporting cancer relevant scientific research with direct benefit to patients and the general public.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA043703-30S1
Application #
10203295
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2023-03-31
Budget Start
2020-09-01
Budget End
2021-03-31
Support Year
30
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Li, Jiayang; Gresham, Kenneth S; Mamidi, Ranganath et al. (2018) Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy. Int J Cardiol 273:168-176
Enane, Francis O; Saunthararajah, Yogen; Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9:912
Lennon, Donald; Solchaga, Luis A; Somoza, Rodrigo A et al. (2018) Human and Rat Bone Marrow-Derived Mesenchymal Stem Cells Differ in Their Response to Fibroblast Growth Factor and Platelet-Derived Growth Factor. Tissue Eng Part A 24:1831-1843
Evans, Daniel R; Venkitachalam, Srividya; Revoredo, Leslie et al. (2018) Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer. Hum Mutat 39:1092-1101
Augestad, Knut M; Keller, Deborah S; Bakaki, Paul M et al. (2018) The impact of rectal cancer tumor height on recurrence rates and metastatic location: A competing risk analysis of a national database. Cancer Epidemiol 53:56-64
Chen, Lechuang; Feng, Zhimin; Yue, Hong et al. (2018) Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat Commun 9:4585
Patel, Rutulkumar; Zhang, Luchang; Desai, Amar et al. (2018) Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure. Leukemia :
Lager, Angela M; Corradin, Olivia G; Cregg, Jared M et al. (2018) Rapid functional genetics of the oligodendrocyte lineage using pluripotent stem cells. Nat Commun 9:3708
Patel, Rutulkumar; Qing, Yulan; Kennedy, Lucy et al. (2018) MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation. Stem Cells Transl Med 7:513-520
Desai, Amar; Zhang, Yongyou; Park, Youngsoo et al. (2018) A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support. Haematologica 103:1054-1064

Showing the most recent 10 out of 1227 publications